Regen BioPharma, Inc. Provides Shareholder Update on Company’s Activities and Direction

(OTC:RGBP) Regen BioPharma, Inc. has recently paid off 2 outstanding convertible notes totaling approximately $60,000. The payoff was funded with proceeds obtained through the issuance of a promissory note to Coventry Enterprises LLC. Regen BioPharma, Inc. entered into a common stock purchase agreement with Coventry Enterprises LLC, providing for an equity financing facility. The Equity Line Agreement allows Coventry Enterprises LLC to purchase up to $10,000,000 of shares of common stock over a 36-month term, subject to the terms and conditions of the agreement and an effective Registration Statement. The company is pursuing joint ventures related to research programs utilizing artificial intelligence modeling for clinical trials. It is anticipated that a nonbinding Letter of Intent will be signed shortly regarding these joint ventures. Regen BioPharma, Inc.'s website appears to have been hacked, and a website developer has been retained to create a new website. The company's X account also appears to have been hacked, impairing the ability to circulate news and updates through social media, and the company is working to remedy this issue. The contact information card on the current website is now working, and shareholders are encouraged to use it for questions or comments. The CEO of Regen BioPharma, Inc. anticipates presenting at the Emerging Markets conference in the near future to provide real-time updates to shareholders.